Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 12, 1998, Pages 652-660

  Buchwald, A ^a   Hochhaus, G ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Pharmacodynamic; Pharmacokinetic; Salmeterol

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR; SALMETEROL XINAFOATE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL PHARMACOLOGY; DRUG POTENCY; PHARMACODYNAMICS; REVIEW;

EID: 0031775153     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 2-adrenoceptor agonist. Br J Pharmacol 92: 746P
2. Barnhart ER 1998 Salmeterol Xinafoate. Physicians' Desk Reference Oradell, New Jersey, pp 108-111
3. Beasley R, Coleman E, Hermon Y, Holst PE, O 'Donnell TV, Tobias M 1988 Viral respiratory tract infection and exacerbations of asthma in adult patients. Thorax 43: 679-683
4. 2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 48: 1121-1124
5. Booth H, Bish R, Walters J, Whitehead F, Walters EH 1996 Salmeterol tachyphylaxis in steroid-treated asthmatic subjects. Thorax 51: 1100-1104
6. Bousquet J, Aubert B, Bons J 1996 Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma. Ann Allergy Asthma Immunol 76: 189-194
7. 2-adrenoceptor agonist. Br J Pharmacol 92: 590P
8. 2-adrenoreceptor stimulant. Lung Suppl: 111-114
9. Britton MG, Earnshaw JS, Palmer JBD 1992 A twelve-month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 5: 1062-1067
10. Brogden RN, Faulds D 1991 Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42: 895-912
11. Carlsen K-H, Røksund O, Olsholt K, Njå F, Leegaard J, Bratten G 1995 Overnight protection by inhaled salmeterol on exercise-induced asthma in children. Eur Respir J 8: 1852-1855
12. Castle W, Fuller R, Hall J, Palmer J 1993 Servent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306: 1034-1037
13. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsivness in patients with mild asthma. N Engl J Med 327: 1198-1203
14. Clark CE, Ferguson AD, Siddorn JA 1993 Respiratory arrest in young asthmatics on salmeterol. Respir Med 87: 227-228
15. 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol Pharmacol 49: 182-189
16. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI 1994 Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 271: 1412-1416
17. Davies BH, Tibbetts HA, Brooks, Devoy MAB 1995 The efficacy and safety of salmeterol compared to theopylline: a meta-analytic integration of nine controlled studies. Eur Respir J 19: 262s
18. Finkelstein FN 1994 Risks of salmeterol? N Engl J Med 331: 1314
19. 2-agonist. Br Med J 301: 1365-1368
20. Fjellbirkeland L, Gulsvik A, Palmer JBD 1994 The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 88: 599-607
21. Greening AP, Ind PW, Northfield M, Shaw G 1994 Added salmeterol versus higher-dose corticesteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344: 219-224
22. Grove A, Lipworth BJ 1995 Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346: 201-206
23. Jack D 1991 The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta-adrenoceptor agonists. Br J Clin Pharmacol 31: 501-514
24. Jenkins MM, Hilton CJ, de Kock JC, Palmer JBD 1991 Exacerbation of asthma in patients on salmeterol. Lancet 337: 913-914
25. Johnson M 1990 The pharmacology of salmeterol. Lung 168: 115-119
26. Johnson M 1995 Salmeterol. Salmeterol Medicinal Research Reviews 15: 225-257
27. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Ostrom NK, Gowarty NA, Cocchetto RN, Cocchetto DM 1989 A comparative study of salmeterol, albuterol, and placebo via MDI in asthmatic adults. J Allergy Clin Immunol 83: 186
28. Kemp JP, Dockhorn RJ, Busse WW, Bleecker ER, van As R 1994 A prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Care Med 150: 1612-1615
29. Langton Hewer S, Hobbs J, Connett G, Lenney W 1994 Salmeterol in the prevention of exercise-induced bronchospasm in preschool children. Eur Respir J 18: 451s
30. Lofdahl CG 1990 Basic pharmacology of new long-acting sympathomimetics. Lung Suppl: 18-21
31. Lundback B, Rawlinson DW, Palmer JBD 1993 Twelve-month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 48: 148-153
32. Maconochie JG, Forster JK 1990 The pharmacological effect of high dose inhaled salmeterol. Br J Clin Pharmacol 29: 632P
33. Maconochie JG, Denyer LH, Hassani H 1994 Dose-related protection against histamine-induced bronchoconstriction by inhaled salmeterol. Int J Clin Pharmacol Ther 32: 329-34
34. Manchee GR, Barrow A, Kulkarni S, Palmer E, Oxford J, Colthup PV, Maconochie JG, Tarbit MH 1993 Disposition of salmeterol xinafoate in laboratory animals and humans. Drug Metab Dispos 21: 1022-1028
35. Mann K 1994 Results of prescription event monitoring study of salmeterol. BMJ 309: 1018
36. Muir JF, Bertin L, Georges D 1992 Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir J 5: 1197-1200
37. Nathan RA 1998 Is the tolerance to the bronchoprotective effect of salmeterol clinically relevant? Ann Allergy Asthma Immunol 80: 1-3
38. 2-adrenoceptor agonists? Br J Pharmacol 99: 120P
39. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J 1997 Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10: 2484-2489
40. 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. Ann Allergy Asthma Immunol 75: 180-184
41. Prévost A, Leper A, More F, Cantle JP, Millard H 1997 Cardiotoxic effects of salmeterol in comparison with salbutamol on the isolated perfused Langendorff-heart of the rat. Arzneim Forsch Drug Res 47: 39-43
42. Sanjar S, McCabe PJ, Humbles AH 1991 Inhibition by salmeterol of antigen-induced eosinophil accumulation in guinea-pig lung. Eur Respir J 4: 200S
43. Sims TA, Thomas TV, Plattenburg PD, Egbunike IG, Jakson DM 1995 Salmeterol xinafoate induced fatal respiratory arrest. Int Pharm Abstr 32: 2325
44. Smyth ET, Pavord ID, Wong CS, Wisniewski AFZ, Williams J, Tattersfield AE 1993 Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 306: 543-545
45. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST 1990 Protection against allergen-induced asthma by salmeterol. Lancet 336: 1338-1342
46. Ullman A, Svedmyr N 1988 Salmeterol, a new long acting inhaled beta2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43: 674-678
47. 2-adrenoceptor agonists. Gen Pharmacol 27: 575-580
48. Whelean CJ, Johnson M 1992 Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol 105: 831-838
49. Wilding P, Clark M, Coon JT, Lewis S, Rushton L, Bennett J, Oborne J, Cooper S, Tattersfield AE 1997 Effect of long-term treatment with salmeterol on asthma control: a double-blind, randomized crossover study. BMJ 314: 1441-1446
50. Woolcock A, Lundback B, Ringdal N, Jacques L 1996 Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153: 1481-1488